Enzyme-Linked Receptors

Enzyme-Linked Receptors - Cell's Smart Sensors

Cell surface receptors with intracellular domains possessing enzymatic activity or directly associating with an enzyme.

• Basic Structure:
  • Extracellular: Ligand-binding domain.
  • Transmembrane: Typically a single-pass α-helix.
  • Intracellular: Catalytic domain or enzyme-association site.
• General Mechanism: Ligand binding → Receptor conformational change (often dimerization) → Intrinsic/associated enzyme activation (e.g., autophosphorylation for RTKs) → Downstream signal cascade.
• Major Classes:
  • Receptor Tyrosine Kinases (RTKs) e.g., Insulin R.
  • Tyrosine Kinase-Associated Receptors (TKARs) e.g., Cytokine R. (JAK-STAT).
  • Receptor Serine/Threonine Kinases e.g., TGF-β R.
  • Receptor Guanylyl Cyclases e.g., ANP R.
  • Receptor Tyrosine Phosphatases e.g., CD45.

⭐ Most enzyme-linked receptors are single-pass transmembrane proteins.

Receptor Tyrosine Kinases - Dimerize & Dominate

• Largest family of enzyme-linked receptors; possess intrinsic tyrosine kinase activity.
• Structure: Extracellular ligand-binding domain, transmembrane helix, intracellular domain with tyrosine kinase activity.
• Mechanism:
  • Ligand binding induces receptor dimerization.
  • Dimerization activates kinase domains, leading to autophosphorylation of tyrosine residues on the cytoplasmic tail.
  • Phosphorylated tyrosines create docking sites for SH2 (Src Homology 2) or PTB (Phosphotyrosine-Binding) domain-containing proteins (e.g., Grb2, PLCγ, PI3K).
• Key Examples:
  • Insulin Receptor (unique: pre-formed dimer)
  • EGFR (Epidermal Growth Factor Receptor)
  • PDGFR (Platelet-Derived Growth Factor Receptor)
  • VEGFR (Vascular Endothelial Growth Factor Receptor)
  • FGFR (Fibroblast Growth Factor Receptor)
• Major Signaling Pathways:
  • MAPK Pathway (Ras-Raf-MEK-ERK): Cell proliferation, differentiation.
  • PI3K-Akt Pathway: Cell survival, growth, metabolism.

⭐ The Insulin Receptor is an RTK that exists as a pre-formed dimer.

JAK-STAT & Other Kinases - Signal Relayers Inc.

• Tyrosine Kinase-Associated Receptors (TKARs): No intrinsic kinase; use cytoplasmic JAKs.
  • Example: Cytokine receptors (Interferons, Interleukins, GH, Prolactin).
  • JAK-STAT Pathway: Cytokine → Receptor dimerization → JAK activation & phosphorylation → STAT recruitment & phosphorylation → STAT dimerization → Nucleus → Gene transcription.
  • 📌 JAK-STAT: Just Activate Kinases, Signal Transducers And Transcription.

![JAK-STAT pathway activation and inhibition](https://ylbwdadhbcjolwylidja.supabase.co/storage/v1/object/public/notes/L1/Biochemistry_Signal_Transduction_Enzyme-Linked_Receptors/a922cea0-6d82-41d1-9276-353c88ab1887.png)

• Receptor Serine/Threonine Kinases: Intrinsic Ser/Thr kinase.
  • Example: TGF-β receptors (Type I & Type II).
  • Mechanism: TGF-β binds Type II → phosphorylates Type I → Type I phosphorylates Smads → Smads complex to nucleus → Gene transcription.
• Receptor Guanylyl Cyclases: Ligand activates guanylyl cyclase.
  • Example: ANP receptor.
  • Converts $GTP \rightarrow cGMP$.

⭐ The JAK-STAT pathway is critical for immune responses and hematopoiesis.

ELR Clinical Significance - Targets & Troubles

• Dysregulation of ELR signaling pathways is implicated in numerous diseases.
• Cancer:
  • Overexpression/mutation of RTKs (e.g., EGFR in lung cancer, HER2 in breast cancer) leads to uncontrolled cell proliferation and survival.
  • Therapeutic strategies:
    • Monoclonal antibodies: Trastuzumab (anti-HER2), Cetuximab (anti-EGFR).
    • Tyrosine Kinase Inhibitors (TKIs): Imatinib (BCR-ABL), Erlotinib (EGFR).
• Inflammatory/Autoimmune diseases:
  • JAK inhibitors (e.g., Tofacitinib) target dysregulated cytokine receptor signaling in conditions like rheumatoid arthritis.
• Developmental disorders:
  • Mutations in FGFRs (e.g., Achondroplasia due to FGFR3 mutation) cause skeletal dysplasias.

⭐ Imatinib, a TKI, revolutionized Chronic Myeloid Leukemia (CML) treatment by targeting the BCR-ABL fusion protein.

High‑Yield Points - ⚡ Biggest Takeaways

• Receptor Tyrosine Kinases (RTKs): Largest class; ligand binding induces dimerization and autophosphorylation.
• Insulin Receptor: A crucial RTK activating PI3K/Akt and MAPK pathways.
• JAK-STAT Pathway: Utilized by cytokine receptors, involving associated Janus kinases.
• Ras Protein: A key small G-protein linking RTK activation to the MAPK cascade.
• Growth Factors: Such as EGF and PDGF, typically signal through RTKs.
• Cancer: Dysregulated RTK signaling (e.g., HER2) is frequently implicated in various malignancies.
• Serine/Threonine Kinase Receptors: Another class, e.g., TGF-β receptors, phosphorylating SMAD proteins.